Recommended Treatment for Erectile Dysfunction
Start with oral PDE5 inhibitors (sildenafil, vardenafil, tadalafil, or avanafil) as first-line therapy for most men with ED, selecting based on intercourse frequency and patient preference, with proper education on dosing, timing, and the need for sexual stimulation. 1, 2
First-Line Treatment: PDE5 Inhibitors
PDE5 inhibitors remain the gold standard for ED treatment based on their excellent efficacy, safety profile, and tolerability 1, 2, 3. All four available agents (sildenafil, vardenafil, tadalafil, avanafil) show comparable effectiveness with no significant differences in efficacy or safety between them 3.
Key implementation points:
- Selection depends on intercourse frequency: Tadalafil's longer half-life suits men with frequent sexual activity, while shorter-acting agents work for occasional use 1
- Dose titration is critical: Titrate to the maximum tolerated dose to increase efficacy and satisfaction 3
- Patient education prevents treatment failure: A large percentage of "non-responders" are actually using the medication incorrectly 2. Emphasize that sexual stimulation is necessary, avoid taking with large meals, and multiple trials may be needed before establishing efficacy 2
Managing PDE5 Inhibitor Non-Responders
Before declaring treatment failure, verify appropriate medication use and timing 1. The algorithmic approach for non-responders:
- First, confirm proper use: Education about dosing and sexual stimulation can restore effectiveness in many cases 1
- Check testosterone levels: In hypogonadal men, combining PDE5 inhibitors with testosterone therapy significantly improves outcomes compared to PDE5 inhibitors alone 2. Note: Testosterone alone is NOT effective monotherapy for ED 2
- Consider switching PDE5 inhibitors: While evidence is limited, some patients may respond to a different agent 1
- Advance to second-line therapies (see below)
Second-Line Therapies
When PDE5 inhibitors fail or are contraindicated, proceed systematically:
Intracavernosal Injection (ICI) Therapy
ICI with alprostadil is the most effective second-line option and should be offered to PDE5 inhibitor non-responders 2, 3.
- Requires in-office test and training before home use 2
- Can use alprostadil alone (FDA-approved) or combination therapy (alprostadil + papaverine + phentolamine) for enhanced efficacy 2
- Mean IIEF-EF improvement of 3.21 points versus placebo 1
Vacuum Erection Devices (VED)
VEDs show 90% initial efficacy but drop to 50-64% satisfaction at 2 years 1, 2.
- Best suited for older patients with infrequent intercourse 1
- Must contain a vacuum limiter for safety 2
- Contraindicated in bleeding disorders or anticoagulation therapy 2
- Common minor adverse effects: penile petechiae, bruising, discomfort, ejaculatory difficulty 2
Intraurethral (IU) Alprostadil
Intraurethral alprostadil achieves 29.5-78.1% successful intercourse rates 2.
- Requires in-office test and dose titration before prescribing 2
- Alternative for patients preferring to avoid oral medications or injections 2
- Less invasive than ICI but generally less effective 3
Adjunctive and Combination Therapies
Low-intensity shockwave therapy (LI-SWT) may be used in men with mild vasculogenic ED and shows benefit in PDE5 inhibitor non-responders 1. Combination with daily tadalafil or VEDs enhances results, suggesting multimodal approaches have merit 1.
Psychosocial interventions (sexual skills training, cognitive behavioral therapy) effectively complement medical treatment and should be integrated when appropriate 1.
Third-Line Treatment: Penile Prosthesis
Penile prosthesis implantation is the gold standard for refractory ED 4.
- Reserved for men who fail or cannot tolerate medical therapies
- Contraindicated in active systemic, cutaneous, or urinary tract infection 2
- Requires thorough counseling on post-operative expectations 2
Essential Diagnostic Workup
Before initiating treatment, obtain:
- Glucose-lipid profile (identifies metabolic syndrome, diabetes) 1
- Morning total testosterone (if not assessed in last 12 months) 1
- Consider bioavailable or free testosterone if total testosterone is borderline 1
Cardiovascular risk assessment is critical: ED often precedes coronary events by 5 years, with coronary lesions found in nearly 80% of men with arterial ED and no known cardiovascular history 5.
Critical Pitfalls to Avoid
- Don't accept initial PDE5 inhibitor "failure" without verifying proper use - incorrect timing, lack of sexual stimulation, and inadequate dosing account for most treatment failures 2
- Don't prescribe testosterone alone for ED - it must be combined with PDE5 inhibitors or other ED therapies 2
- Don't prescribe ICI or IU alprostadil without in-office testing and training - this is a clinical principle, not optional 2
- Warn patients about counterfeit medications from unauthorized sources - these are potentially dangerous 3